Editas Medicine Total Cash From Operating Activities Over Time
| EDIT Stock | USD 2.38 0.06 2.46% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Editas Medicine Performance and Editas Medicine Correlation. Editas |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Editas Medicine. If investors know Editas will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Editas Medicine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.54) | Revenue Per Share 0.752 | Quarterly Revenue Growth (0.99) | Return On Assets (0.34) | Return On Equity (0.79) |
The market value of Editas Medicine is measured differently than its book value, which is the value of Editas that is recorded on the company's balance sheet. Investors also form their own opinion of Editas Medicine's value that differs from its market value or its book value, called intrinsic value, which is Editas Medicine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Editas Medicine's market value can be influenced by many factors that don't directly affect Editas Medicine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Editas Medicine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Editas Medicine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Editas Medicine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Total Cash From Operating Activities Analysis
Compare Editas Medicine and related stocks such as Beam Therapeutics, Crispr Therapeutics, and Caribou Biosciences Total Cash From Operating Activities Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BEAM | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (20.3 M) | (72 M) | (95.7 M) | (66.3 M) | 22.5 M | (149.2 M) | (141.7 M) |
| CRSP | (4.8 M) | (4.8 M) | (4.8 M) | (4.8 M) | (4.8 M) | 59.4 M | (55.3 M) | (70.1 M) | (96.2 M) | 56.7 M | (238.4 M) | 539 M | (495.7 M) | (260.4 M) | (247.4 M) |
| CRBU | (32 M) | (32 M) | (32 M) | (32 M) | (32 M) | (32 M) | (32 M) | (32 M) | (32 M) | (32 M) | (33.2 M) | (32.5 M) | (91 M) | (93.3 M) | (88.6 M) |
| VERV | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (35.3 M) | (77.9 M) | (122.3 M) | (149.5 M) | (142.1 M) |
| NTLA | (3.5 M) | (3.5 M) | (3.5 M) | (3.5 M) | (3.5 M) | (1.8 M) | 36.1 M | (65.3 M) | (61.3 M) | (103.2 M) | (49.9 M) | (225 M) | (333.3 M) | (394.1 M) | (374.4 M) |
| VRTX | (2.5 M) | 143.7 M | 267.8 M | (51.6 M) | (513.2 M) | (365.4 M) | 236.1 M | 844.9 M | 1.3 B | 1.6 B | 3.3 B | 2.6 B | 4.1 B | 3.5 B | 3.7 B |
| DNA | (44.7 M) | (44.7 M) | (44.7 M) | (44.7 M) | (44.7 M) | (44.7 M) | (44.7 M) | (44.7 M) | (44.7 M) | (44.7 M) | (135.8 M) | (253.8 M) | (252.2 M) | (295.5 M) | (310.3 M) |
| ALLO | (44.7 M) | (44.7 M) | (44.7 M) | (44.7 M) | (44.7 M) | (44.7 M) | (44.7 M) | (44.7 M) | (44.7 M) | (137.3 M) | (115.1 M) | (184.8 M) | (220.5 M) | (237.7 M) | (225.8 M) |
| SANA | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (85.5 M) | (138 M) | (251.1 M) | (290.1 M) | (253.6 M) | (266.3 M) |
Editas Medicine and related stocks such as Beam Therapeutics, Crispr Therapeutics, and Caribou Biosciences Total Cash From Operating Activities description
My Equities
My Current Equities and Potential Positions
| Editas Medicine | EDIT |
| Classification | Pharmaceutical Products |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 2.38
Additional Tools for Editas Stock Analysis
When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.